

Adding ImmunoCAP™ Der p 23* to your test profile

House Dust Mite


Allergens for AIT**? Risk for asthma?

Knowing the sensitization profile can help you decide on patient management.¹⁻⁴

By adding ImmunoCAP™ Der p 23* to your test profile you can improve diagnostic certainty.⁴⁻⁶

*ImmunoCAP Allergen d209, Allergen component rDer p 23, House dust mite

** Allergen Immunotherapy



Find out more at thermoscientific.com/phadia

ImmunoCAP®
ALLERGEN COMPONENTS

ThermoFisher
SCIENTIFIC

ImmunoCAP™
Whole Allergens

ImmunoCAP™
Allergen Components

Clinical implications

Dermatophagoides pteronyssinus (d1) and Dermatophagoides farinae (d2)

Der p 1* (d202) / Der p 2* (d203) / Der p 23* (d209)

Specific markers

Der p 10 (d205)

Cross reactive marker

Choice of AIT

- Differentiation between Der p 1, 2 and 23 sensitization helps choose appropriate AIT.^{1,2}
- Der p 2 sensitized patients may benefit from AIT based on purified mite body cultures⁷⁻⁹ or carefully standardized pharmaceuticals.^{10,11}
- Der p 23 amount in fecal particles/bodies is low and may therefore be underrepresented[#] in AIT.⁶

Assess risk for asthma

- Early sensitization to Der p 1, 2 & 23 is associated with asthma development.³
- Asthmatic patients are sensitized to more components than those without asthma.⁴

Further examination needed

- Cross-reactivity between HDM, crustaceans, insects and molluscs.
- If Der p 10 is dominant, food allergy can be suspected.

1. Asero R. Eur Ann Allergy Clin Immunol. 2012;44(5):183–7. 2. Schmid-Grendelmeier P. Hautarzt. 2010;61(11):946–53. 3. Posa D, et al. J Allergy Clin Immunol. 2017;139:541–94. 4. Resch Y, et al. J Allergy Clin Immunol. 2015;136:1083–91. 5. Becker S, et al. Int Arch Allergy Immunol. 2016;170(2):132–7. 6. Weghofer M, et al. J Immunol. 2013;190(7):3059–67. 7. Brunetto R, et al. Allergy 2010;65:184–90. 8. Casset A, et al. Int Arch Allergy Immunol. 2012;159:253–62. 9. Weber B, et al. Allergy. 1998;53 (Suppl 43):25. 10. Henmar H, et al. Int Arch Allergy Immunol. 2016;169(1):23–32. 11. Canonica GW, et al. Expert Rev Clin Immunol. 2016 Aug;12(8):805–15. *High cross-reactivity between Der p 1/Der f 1, Der p 2/Der f 2, Der p 23 / Der f 23. #Der p 23 content of extracts has not been studied.